Myasthenia Gravis (MG) Market in China 2023
Myasthenia gravis (MG) is a rare autoimmune disorder that affects the muscles responsible for movement and breathing. It is caused by antibodies that attack the receptors on the muscles, preventing them from receiving the signals from the nerves that control them. This leads to muscle weakness and fatigue, particularly in the eyes, face, throat, and limbs. The symptoms of MG can vary widely between individuals, and can include drooping eyelids, double vision, difficulty speaking and swallowing, weakness in the arms and legs, and respiratory problems. Treatment for MG typically involves medications that improve the communication between the nerves and muscles, such as acetylcholinesterase inhibitors and immunosuppressants. In severe cases, plasmapheresis or intravenous immunoglobulin therapy may be used to remove or block the antibodies that are attacking the muscles. The myasthenia gravis in China market is expected to increase by USD 639.2 million, at a compound annual growth rate (CAGR) of 45.27% from 2023 to 2029, according to the latest edition of the Myasthenia Gravis Market in China Report.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on myasthenia gravis can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The competitive landscape of the market is highly consolidated and dominated by key players such as HBM Holdings Limited, Rongchang Pharmacy Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Myasthenia Gravis Market
Identify segments/areas to invest in over the forecast period in the China Myasthenia Gravis Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on myasthenia gravis can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.
The competitive landscape of the market is highly consolidated and dominated by key players such as HBM Holdings Limited, Rongchang Pharmacy Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Myasthenia Gravis Market
Identify segments/areas to invest in over the forecast period in the China Myasthenia Gravis Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Myasthenia gravis market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
HBM Holdings Limited
Rongchang Pharmacy Co., Ltd.
Part 6. Methodology
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Myasthenia gravis market overview
Part 4. Market breakdown by region
Central South China
East China
North China
Northeast China
Northwest China
Southwest China
Part 5. Key companies
HBM Holdings Limited
Rongchang Pharmacy Co., Ltd.
Part 6. Methodology
